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Abstract Healthcare-associated pneumonia (HCAP) has
been proposed as a new category of pneumonia distinct
from community-acquired pneumonia (CAP). A multi-
center observational study in 2008 finds that patients with
HCAP have a mortality rate significantly higher than
patients with CAP, and a worse outcome is associated at
logistic regression analysis with a low adherence to
empirical antibiotic therapy recommended by ATS/IDSA
guidelines. We designed a prospective interventional study
to establish whether administration of a broad-spectrum
antibiotic therapy consistent with the 2005 ATS/IDSA
guidelines has an effect on the clinical outcome of hospi-
talized patients with HCAP. All patients with HCAP pro-
spectively admitted in 25 medical wards of 20 Italian
hospitals during a 1-month period were included in the
study. All patients were assigned to receive an empirical
therapy including a fluoroquinolone plus an anti-MRSA
agent plus either piperacillin–tazobactam or a carbapenem.
Main measures for improvement were duration of antibi-
otic therapy, length of hospital stay, and in-hospital mor-
tality rate. Patients were compared with a historical control
group of 90 patients, and followed up to discharge or death.
HCAP patients receiving a guideline-concordant therapy
had a shorter duration of antibiotic therapy (median 15 vs.
12 days, p = 0.0002), a shorter duration of hospitalization
(median 18 vs. 14 days, p = 0.02), and a lower mortality
rate (17.8 vs. 7.1 %, p = 0.03). Our results suggest that
an empirical broad-spectrum therapy is associated with
improved outcome in patients with HCAP.
Keywords Healthcare-associated pneumonia 
Community-acquired pneumonia  Antibiotic therapy 
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Introduction
Classically, pneumonia represents a spectrum of diseases
that range from community-acquired to hospital-acquired
and ventilator-associated pneumonia. The 2005 American
Thoracic Society (ATS)/Infectious Diseases Society of
America (IDSA) guidelines [1] incorporated for the first
time the new concept of healthcare-associated pneumonia
(HCAP) that includes patients who have recent or chronic
contact with health care system, such those living in
nursing homes, attending hemodialysis clinics, receiving
parental therapy in the 30 days before pneumonia, or with a
history of recent hospitalization within 90 days). Several
studies have provided original data about this topic [2–12],
and the published literature suggests that patients with
disease that falls under the HCAP definition have a sig-
nificantly higher in-hospital mortality than those classified
as having ‘‘true’’ CAP. The increased mortality seems to be
associated with a greater likelihood to receive an inap-
propriate empirical antibiotic therapy [2, 8, 11–14], and
one critical disparity between the two groups of patients
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appears to be a higher incidence of infection with multi-
drug resistant (MDR) pathogens in the HCAP group [1, 11,
12, 15–18].
For the initial empirical treatment of patients with
HCAP, the 2005 ATS/IDSA guidelines recommend the
administration of broad-spectrum antibiotics [1]. This is the
same strategy as that recommended for patients with hos-
pital-acquired pneumonia (HAP) and ventilator-associated
pneumonia (VAP), both groups with risk factors for MDR
pathogens. In a multicenter, prospective observational
study [13], we ascertained the epidemiology and outcome
of CAP, HCAP and HAP in adult patients hospitalized in
Italian internal medicine wards. Compared with patients
who had CAP, patients with HCAP have a greater severity
of clinical conditions, a significantly higher mean duration
of antibiotic therapy, a higher length of hospital stay, and
higher mortality rates. At multivariate analysis, the receipt
of an empirical antibiotic therapy not recommended by
international guidelines is the main factor independently
associated with increased intra-hospital mortality [OR 6.4
(CI 2.3–17.6)].
The present study is a multicenter interventional study
evaluating the clinical effectiveness of an empirical broad-
spectrum antibiotic therapy for the treatment of HCAP.
Patients and methods
Setting and period of study
We planned a multicenter study in those divisions of
internal medicine to evaluate the clinical effectiveness of
an empirical broad-spectrum antibiotic therapy for the
treatment of HCAP. To this end, we performed a before–
after study by comparing a prospective interventional
group with an historical one. The interventional study was
performed in 25 divisions of internal medicine in 20 Italian
hospitals during a 1-month period (1–28 February 2009).
Prior to the start of the study, at least one physician from
each center participated in a single-day investigator meet-
ing. Participating centers were geographically distributed
across various regions of the North, Central or South of
Italy. All patients enrolled in the study were compared with
a group of 90 patients with HCAP enrolled in a previous
prospective observational study (historical control group).
Cases of pneumonia of the latter group were assessed
during two active 1-week surveillance study periods
(22–29 January and 25 June–2 July 2007). All the physi-
cians who participated in the interventional study took part
in the first study that enrolled the patients of the historical
control group.
The study was done in accordance with the International
Conference on Harmonization guidelines on Good Clinical
Practice and the principles of the Declaration of Helsinki.
The study was registered on the website of the Italian
Medicines Agency (Osservatorio Nazionale per la Speri-
mentazione dei Medicinali, AIFA), EudraCT number
2009-016476-67, and was approved by the independent
ethics committee or institutional review board at all par-
ticipating institutions. The study comprised only adult
patients ([18 years) with HCAP who were hospitalized in
internal medicine wards during a 4-week period (1 Feb-
ruary–1 March 2010).
Patients
Our inclusion criteria were radiologic evidence of pneu-
monia, and at least two of the following criteria: fever or
hypothermia (temperature [38 C or \35 C), dyspnea,
cough and purulent sputum, pleuritic chest pain, or signs of
consolidation on respiratory auscultation. We classified
patients as having HCAP if they had been admitted to an
acute-care hospital for at least 2 days in the prior 180 days,
or resided in a long-term care facility (LTCF), or had
attended a hospital or hemodialysis clinic, or had received
intravenous therapy (included antibiotics) in the prior
30 days [13]. Exclusion criteria included acquisition of
pneumonia in the intensive care unit (ICU) or in another
hospital and HIV infection.
Measurements
To stratify patients into risk classes, we used the prediction
rule calculated according to the PSI and the CURB-65
scores. We recorded the following data: age, gender,
intrinsic and extrinsic risk factors, clinical signs and
symptoms, results from laboratory studies, chest radiogra-
phy pattern, results of microbiologic studies, antibiotic
therapy, and outcome. Severity of clinical conditions was
assessed at the time of presentation using the SOFA score.
Microbiological studies
All patients included in the study underwent the following
diagnostic procedures: blood cultures, Legionella pneu-
mophila serogroup 1 antigen in urine, and sputum culture
(if available). Further studies such as S. pneumoniae anti-
gen in urine, standard serologic methods to determine
antibodies against atypical agents, pleural fluid culture, or
culture of bronchoalveolar lavage (BAL) were performed
on the basis of the availability of the above-mentioned
methods or according to the judgment of the attending
physician.
Microbiological data were culture results from the first
48 h after admission to hospital. An etiologic diagnosis
was considered definitive if one of the following criteria
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was met: (1) blood cultures yielded a bacterial pathogen (in
the absence of an apparent extrapulmonary focus); (2)
pleural fluid and transthoracic needle aspiration culture
yielded a bacterial pathogen; (3) respiratory sample rep-
resentative of the lower respiratory tract (fiberoptic bron-
choscopy with protected catheter) yielded a bacterial
pathogen; (4) isolation of L. pneumophila in sputum or
detection of L. pneumophila serogroup 1 or pneumococcal
antigen in urine; (5) fourfold increase in the antibody titer,
or seroconversion for atypical pathogens. An etiologic
diagnosis was considered presumptive when a predominant
microorganism was isolated from a purulent sputum sam-
ple [presence of [25 polymorphonuclear leukocytes and
\10 squamous cells per low-power field (original magni-
fication 910)] with compatible Gram’s stain findings.
Presumptive aspiration pneumonia was diagnosed on a
clinical and radiological basis in patients who had risk
factors such as compromised consciousness, altered gag
reflex, dysphagia, severe periodontal disease, putrid spu-
tum, or necrotizing pneumonia in absence of positive
respiratory specimens cultures.
The following pathogens were considered as multi-drug
resistant (MDR): methicillin-resistant Staphylococcus
aureus (MRSA), extended-spectrum b-lactamase (ESBL)
producing Gram-negative Enterobacteriaceae, Pseudomo-
nas aeruginosa, Acinetobacter baumannii, Stenotropho-
monas maltophilia and other Enterobacteriaceae spp.
resistant for three or more of the following antibiotic
classes: antipseudomonal cephalosporins or penicillins,
carbapenems, fluoroquinolones and aminoglycosides.
Antimicrobial treatment
All patients with diagnosis of HCAP were assigned to
receive an empirical antibiotic therapy as follows: a
fluoroquinolone (ciprofloxacin 400 mg i.v. every 8 h or
levofloxacin 750 mg i.v. every 24 h) plus an anti-methi-
cillin-resistant Staphylococcus aureus (MRSA) agent
(vancomycin 1 g i.v. every 12 h or linezolid 600 mg i.v.
every 12 h) and either an antipseudomonal b-lactam
(piperacillin–tazobactam 4.5 g i.v. every 8 h) or a carba-
penem (imipenem 500 mg i.v. every 6 h or meropenem 1 g
i.v. every 8 h). Drug dosages were modified according to
the creatinine clearance calculated using the Cockroft–
Gault formula. Dose adjustments of vancomycin based on
renal function and vancomycin serum concentrations were
left to the individual judgment of the clinicians at the dif-
ferent study sites. Treatment was performed for at least
7 days; a prolonged treatment was given if deemed neces-
sary by the attending physician. Treatment was discontin-
ued if any underlying disease or infection was exacerbated,
efficacy of treatment was inadequate, or the condition
was exacerbated, incidental symptoms developed, adverse
reactions or laboratory abnormalities developed, the patient
or his/her proxy requested discontinuation, or if the
attending physician considered discontinuation necessary
for other reasons. In cases in which an etiological diagnosis
was obtained, antibiotic therapy was de-escalated on the
basis of microbiological results.
Statistical analysis
Data are presented as median values (interquartile range)
for quantitative variables and as absolute and relative fre-
quencies (95 % CI) for categorical variables. Data obtained
in the study group (interventional group) were compared
with a historical control represented by 90 patients pro-
spectively investigated in a previous study [13, 19]. We
performed the Mann–Whitney U test for comparisons
between quantitative variables and the Pearson Chi-square
test or the generalized Fisher exact test for contingency
table analysis. We investigated the association between in-
hospital mortality (as outcome variable) and all the other
collected variables using multivariate logistic regression.
We used the Hosmer–Lemeshow methodology for variable
selection as previously reported [19]. All the significant
variables were put into the final model of multivariate
logistic regression analysis. We performed the Pearson
goodness-of-fit test to assess the overall fit of the model.
We computed odds ratios (ORs) derived from the covari-
ates, and their confidence intervals using a clustered robust
standard error estimation. A cluster includes all the cases
from one participating ward. Relationships between the
primary outcome variable and each of the continuous ones
were investigated by fractional polynomial logistic
regression analysis; continuous variables were eventually
transformed accordingly before being put into the multi-
variate regression model. A 2-tailed p value of less than
0.050 was considered statistically significant for all the
analyses. We used STATA/SE, version 9.2 for Windows
(StataCorp, College Station, TX, USA), to analyze the data.
Results
In total, 127 subjects with HCAP who were admitted to the
study hospitals were included in the study. The median age
was 78 years (range 18–100 years) and 54.3 % of the
patients were men. The backgrounds of the 127 patients are
shown in Table 1.
Table 2 shows clinical characteristics of 90 patients
included in the historical control group and 127 in the
intervention group. Overall, patients did not significantly
differ in terms of median age, sex distribution, underlying
diseases, clinical or laboratory findings. The only differ-
ences were represented by a higher incidence of heart
Intern Emerg Med (2012) 7:523–531 525
123
failure (p = 0.009) and bilateral involvement at chest
radiograph (p = 0.01) in the historical control group, while
renal failure was more frequent in the intervention group
(p = 0.04). Three patients (3.3 %) of the first group and
five patients (4.2 %) of the second group received non-
invasive mechanical ventilation.
Table 3 summarizes microbiological findings. There
were no differences in the percentage of patients with
established etiological diagnosis (31.1 vs. 32.3 %) between
study groups. S. aureus was the most common pathogen
(39.3 vs. 24.4 %), and the rate of methicillin resistance was
63.6 % in the pre-intervention and 70 % in the intervention
group. Gram-negative bacilli were also frequent, mainly
represented by Enterobacteriaceae (31.7 % of cases) and,
less frequently, by P. aeruginosa (12.2 %). Among
Enterobacteriaceae species isolated, 69.2 % were ESBL-
Table 1 Criteria for the diagnosis of healthcare-associated pneumonia
Criterium Historical control group (n = 90) Intervention group (n = 127) p
Recent hospitalization within 180 days 78 (86.7 %) 100 (78.7 %) 0.134
Nursing home resident 10 (11.1 %) 22 (17.3 %) 0.203
Hemodialysis 3 (3.3 %) 3 (2.4 %) 0.667
Intravenous therapy in the 30 days before pneumonia 6 (6.7 %) 8 (6.3 %) 0.907
Data are shown as absolute frequency and percentage (%)
Table 2 Clinical characteristics
of patients
The bold values refer to p values
that are statistically significant
Age is shown as median
(1 quartile–3 quartile);
categorical variables are shown
as absolute frequency and
percentage (%)
Variable Historical control group
(n = 90)
Intervention group
(n = 127)
p
Age, median years 79.5 (72.0–84.0) 78 (70.0–84.0) 0.281
Men 56 (62.2 %) 69 (54.3 %) 0.256
Adherence to international guidelines 24 (26.7 %) 127 (100 %) <0.001
COPD 27 (30 %) 49 (38.6 %) 0.296
Heart failure 34 (37.8 %) 27 (21.3 %) 0.009
Dementia 19 (21.1 %) 32 (25.2 %) 0.530
Renal failure 23 (25.6 %) 51 (40.2 %) 0.044
Diabetes mellitus 24 (26.7 %) 34 (26.7 %) 0.987
Neoplasm 23 (25.6 %) 32 (25.2 %) 0.951
Chronic liver disease 11 (12.2 %) 8 (6.3 %) 0.189
Malnutrition 20 (22.2 %) 18 (14.2 %) 0.081
Etiological diagnosis 28 (31.1 %) 41 (32.3 %) 0.875
Depression of consciousness 24 (26.7 %) 23 (18.1 %) 0.217
Histamine type 2 blockers or antacids 48 (53.3 %) 65 (51.2 %) 0.845
Aerosolized drugs 24 (26.7 %) 31 (24.4 %) 0.814
Previous antibiotic therapy 35 (38.9 %) 52 (40.9 %) 0.721
Fever 41 (45.6 %) 67 (52.8) 0.362
Dyspnea 63 (70 %) 89 (70.1 %) 0.992
Cough 55 (61.1 %) 84 (66.1 %) 0.433
Purulent sputum 33 (36.7 %) 47 (37 %) 0.958
Pleuritic chest pain 11 (12.2 %) 17 (13.4 %) 0.818
Leukopenia 4 (4.4 %) 6 (4.7 %) 0.925
Leukocytosis 47 (52.2 %) 83 (65.4) 0.170
Bilateral involvement at chest radiograph 31 (34.4 %) 25 (19.7) 0.014
Multilobar infiltrates 25 (27.8 %) 39 (30.7) 0.665
Pleural effusion 41 (45.6 %) 47 (37 %) 0.211
Endotracheal intubation within the
previous 30 days
2 (2.2 %) 2 (1.6 %) 0.760
Tracheostomy 1 (1.1 %) 1 (0.8 %) 0.810
Presumptive aspiration pneumonia 22 (24.4 %) 30 (23.6 %) 0.888
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producing strains (5 Klebsiella spp., 2 E. coli, 2 E. cloa-
cae), and additionally one Morganella spp., one Entero-
bacter cloacae and one Klebsiella ozenae were classified as
MDR.
Table 4 describes the risk stratification of patients cal-
culated by use of PSI and CURB-65 scores. Most patients
of both groups were included in the high-risk classes of PSI
(IV and V) and CURB-65 (class III) severity scores.
However, patients of the intervention group had
significantly higher mean values of their PSI score
(p \ 0.01). Table 5 describes the antibiotic regimens
administered in patients with HCAP of the historical con-
trol group. Table 6 shows data on antimicrobial therapy
and outcomes of the two HCAP groups. Among patients
included in the intervention group, vancomycin (83.5 %)
was the more common anti-MRSA agent used, piperacillin/
tazobactam (81.1 %) was the most prevalent anti-Gram-
negative agent (meropenem 10.2 %, imipenem 8.7 %),
while levofloxacin (77.2 %) was the most commonly
fluoroquinolone used. Vancomycin treatment was discon-
tinued in five cases (3.9 %) for renal toxicity and substi-
tuted with linezolid, levofloxacin was discontinued in two
cases and ciprofloxacin in one case for allergic reactions.
Compared to patients included in the historical control
group, those included in the intervention group had a
shorter duration of antibiotic therapy (median 15 vs.
12 days, p = 0.0002, a shorter duration of hospitalization
(median 18 vs. 14 days, p = 0.02), and a lower mortality
rate (17.8 vs. 7.1 %, p = 0.03).
Figure 1 shows ORs and 95 % confidence intervals of
the variables that were significantly and independently
associated with in-hospital mortality at the multivariate
logistic regression analysis.
Discussion
The first goal of our study was a ‘‘real-time’’ analysis of the
clinical approaches of physicians attending hospitalized
patients with HCAP with the aim of evaluating the efficacy
of a new treatment protocol. The 2005 ATS/IDSA guide-
lines [1] incorporated for the first time the new concept of
HCAP that includes patients who have recent or chronic
contact with health care system, such as those living in
nursing homes, attending hemodialysis clinics, receiving
parental therapy in the 30 days before pneumonia, or with a
history of recent hospitalization within 90 days. The find-
ings of our study suggest that administration of a broad-
Table 3 Frequency of microbial pathogens in patients with etiolog-
ical diagnosis
Microorganism Historical
control
group
(n = 28)
Intervention
group
(n = 41)
S. aureus 11 (39.3 %) 10 (24.4 %)
MRSA 7 (25 %) 7 (17 %)
S. pneumoniae 2 (7.1 %) 5 (12.2 %)
Gram-negative bacteria
P. aeruginosa 2 (7.1 %) 5 (12.2 %)
Enterobacteriaceae 9 (32.1 %) 13 (31.7 %)
E. coli 3 (10.7 %) 3 (7.3 %)
Klebsiella spp. 4 (14.3 %) 6 (14.6 %)
Enterobacter cloacae 2 (7.1 %) 3 (7.3 %)
Morganella spp. 1 (3.6 %) 1 (2.4 %)
ESBL 5 (17.9 %) 9 (22 %)
H. influenzae/parainfluenzae 1 (3.6 %) 1 (2.4 %)
Stenotrophomonas maltophilia 0 1 (2.4 %)
Atypical bacteria
Mycoplasma, Chlamydia,
Legionella spp.
1 (3.6 %) 4 (9.8 %)a
Others 2 (7.1 %)b 2 (4.9 %)c
Data are shown as absolute frequency and percentage (%)
a All four cases in the intervention group were due to Legionella
infection
b 1 atypical mycobacterium, 1 M. tuberculosis
c 2 M. tuberculosis
Table 4 Risk stratification of patients at admission
Variable Historical control group (n = 90) Intervention group (n = 127) p
Median PSI score 119 (106–140) 135 (118–160) 0.0001
Median SOFA score 3 (2–4) 3 (1–4) 0.719
PSI high risk classesa 82 (91.1 %) 127 (100 %) 0.963
CURB-65 high risk classb 27 (30.0 %) 30 (23.6 %) 0.43
The bold values refer to p values that are statistically significant
Scores are shown as median (1 quartile–3 quartile); classes are shown as absolute frequency and percentage (%)
PSI pneumonia severity index, SOFA sequential organ failure assessment, CURB-65 confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of
age and older
a Classes IV or V
b Class III
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spectrum empirical therapy, including MRSA and poten-
tially MDR Gram-negative bacilli coverage, is associated
with shorter hospital stay (mean 18 vs. 14 days; p = 0.03),
shorter duration of antibiotic therapy (mean 15 vs. 12 days;
p \ 0.0002), and lower mortality rates (17.8 vs. 7.1 %;
p = 0.03). These results seem to confirm a benefit of the
antibiotic strategy recommended for HAP/VAP among
patients with HCAP.
A recent review discussed the evidence supporting the
role of MDR bacteria in patients with HCAP, and the
strength of the evidence for the individual risk factors
linking them with the presence of MDR pathogens [15].
Different international studies [2, 6–9, 11] seem to share
the message that a percentage of patients with HCAP have
a high likelihood of receiving an inappropriate empirical
antibiotic therapy due to a greater risk of infection with
MDR pathogens. However, the major limitation of these
studies is that an etiologic diagnosis was performed only in
a minority of patients with HCAP (about 30–40 % of cases
in the published articles), and also our prospective study
identified the causative pathogens only in about 30 % of
cases. Thus, microbiological data from patients with cul-
ture-positive pneumonia could not be representative of all
cases of HCAP.
The concept of HCAP may be much more complex and
heterogeneous than to date believed, and many authors
have expressed concern that antibiotic treatment decisions
driven by the concept of HCAP might lead to excessive
prescription and abuse of broad-spectrum anti-infectives
[20] leading to unnecessary costs and promote resistance.
To address this limitation of the HCAP concept, Shorr and
collegues hypothesize that a risk-score approach is more
accurate than the complete HCAP definition, and, conse-
quently, would result in fewer patients being given broad-
Table 5 Antibiotics used in patients included in the historical control
group
Antibiotic n %
Ceftriaxone 24 26.7
Ceftriaxone plus macrolide 15 16.7
Respiratory fluoroquinolonea 14 15.5
Beta lactam plus beta-lactamase inhibitorb 8 8.9
Glycopeptide or linezolid plus fluoroquinolone plus either
an antipseudomonal b-lactam or a carbapenem
24 26.7
a Levofloxacin or moifloxacin
b Amoxicillin/clavulanic acid, ampicillin/sulbactam, piperacillin/
tazobactam
Table 6 Antimicrobial therapy
and outcomes
The bold values refer to p values
that are statistically significant
Days are shown as median
(1 quartile–3 quartile);
categorical variables are shown
as absolute frequency and
percentage (%)
Variable Historical control group
(n = 90)
Intervention group
(n = 127)
p
Median duration of antibiotic
therapy, days
15 (11–19) 12 (10–16) 0.0002
Median duration of hospitalization,
days
18.0 (11.0–22.0) 14.0 (10.0–21.0) 0.0298
Inappropriate antibiotic therapy 18.9 (10–27.8) 4.4 (2.6–6.2) <0.001
Hypotension 87 (96.7 %) 116 (91.3 %) 0.115
ICU transfer 4 (4.4 %) 2 (1.6 %) 0.238
Overall in-hospital mortality rate 16 (17.8 %) 9 (7.1 %) 0.030
0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Aspiration Pneumonia 4.94 (1.71, 14.27)
)74.41,66.1(09.4noisuffElaruelP
)55.121,78.1(70.51shtnom6suoiverpehtninoitazilatipsoH
Residence in a long term facility 8.69 (1.63, 46.42)
Sofa >5 5.62 (1.89, 16.65)
interventional Group 0.22 (0.07, 0.66)
OR (95% CI)ORFig. 1 Factors independently
associated with in-hospital
mortality at multivariate logistic
regression analysis (only
significant variables are shown
in this final model)
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spectrum antibiotic therapy unnecessarily [21]. They assign
points as follows: 4 for recent hospitalization, 3 if pre-
senting from a LTC facility, 2 if chronic HD, 1 if admitted
to the ICU within 24 h of evaluation in the ED, for a
possible maximum score of 10. Analyzing retrospectively a
cohort including 977 patients, the authors find that as the
score increases, the probability of recovering a resistant
organism also increases. As a screening test for resistant
organisms, a score = 0 has a high negative predictive
value (84.5 %) and leads to fewer patients unnecessarily
receiving broad-spectrum antibiotics. Similarly, Aliberti
and colleagues [22] evaluated, in a prospective study, risk
factors for acquiring MDR bacteria among patients coming
from the community who were hospitalized with pneu-
monia. The authors, moreover, evaluated patients’ clinical
outcome during hospitalization, and developed a risk-
scoring tool to identify subjects with pneumonia caused by
MDR organisms. A total of 935 patients with pneumonia
were enrolled in the study of whom 437 (51 %) had at least
1 risk factor for acquiring MDR bacteria on admission.
Among all risk factors, hospitalization in the preceding
90 days (OR 4.87) and residency in a nursing home (OR
3.55) are independent predictors for an actual infection
with a resistant pathogen. A simple score ranging from 0 to
12.5 and performed on admission to the hospital was used
to stratify patients into different classes based on the
probability of having MDR pneumonia. Among patients
with a score B0.5 on entry (low risk class), the prevalence
of a resistant bacteria is 8 % (95 % CI 2–13 %), compared
with 38 % (95 % CI 25–50 %) in those with a score of C3
(p \ 0.001). These recent studies may, in part, explain the
successful outcome observed in our interventional study
group, since more than 90 % of our patients, on the basis of
risk factors, had high values of Shorr and Aliberti risk
scores, and thus high probability of MDR pathogens. This
finding is probably related to the fact that we analyzed only
patients admitted to Internal Medicine wards, who are
usually older and more disabled than those hospitalized in
other medical wards.
In addition, a low incidence of etiological diagnosis in
HCAP patients may be, in part, explained by a significant
percentage of infections by anaerobic bacteria, which are
not routinely cultured in respiratory specimens. All previ-
ously published studies report that HCAP patients are
usually older, more disabled, and with multiple risk factors
for aspiration pneumonia, such as deterioration of con-
sciousness, or need for a feeding tube. A previous study
analyzing swallowing function reports a high incidence of
aspiration pneumonia among hospitalized patients with a
history of prior hospitalization for at least 2 days in the
preceding 90 days or a stay at a nursing home or LTCF
[23]. A high incidence (20.6 %) of probable aspiration
pneumonia is also documented in the studies of Carratala`
[2] and Shindo (58.2 %) [11]. HCAP patients appear then
at high risk for infections by anaerobic bacteria, and a
misdiagnosed high incidence of aspiration pneumonia due
to anaerobic bacteria may explain the improved outcome
observed in our study since all patients received a b-lactam
with extended activity against anaerobic pathogens
(piperacillin–tazobactam or a carbapenem). Most antibiot-
ics recommended for the treatment of CAP (such as third-
generation cephalosporin, macrolides, or levofloxacin) do
not ensure adequate anti-anaerobic coverage. The patients
included in the historical control group had a higher inci-
dence of heart failure, and the presence of bilateral
involvement on chest radiograph; both these conditions
may affect survival in CAP patients [24], and thus may be,
in part, responsible for the increased mortality observed in
the historical control group. However, at regression logistic
analysis, these factors were not significantly associated
with poor outcome.
The design of this study and the use of an historical
control group as comparator may also, in part, explain the
improved clinical outcome observed in the intervention
group of patients. The before–after study is the most
common design encountered in quality improvement
research, but many potentially relevant changes may occur
between ‘‘before’’ and ‘‘after’’ periods of measurement. For
example, all physicians included in the prospective inter-
ventional study initially received scientific materials dis-
cussing the epidemiology and outcome of HCAP, then
participated in an educational event leading to a better
understanding of the correct clinical approach to patients
with CAP and HCAP. Participants were also skilled about
diagnostic procedures, drug dosages, and adjustment of
drugs in the presence of a reduced creatinine clearance.
The primary goal of our study was an evaluation of the
clinical approaches of physicians attending hospitalized
patients with HCAP, with an aim of recognizing incorrect
behaviors, and to evaluate the efficacy of the new ATS/
ISDA recommendations. In this regard, our study confirms
the benefit of educational programs for quality improve-
ment in clinical practice. However, the pneumonia severity
index at admission was greater in the intervention group
than in the historical control group, and such difference
would probably strengthen the results of our study,
reducing the risk of misleading results.
To compare the interventional group with the historical
one, we used 180 days as a cut-off for recent hospitaliza-
tion to differentiate between CAP and HCAP. This is dif-
ferent from ATS criteria (hospitalization in the preceding
90 days), and may be another potential limitation of our
study. The choice of expanding the inclusion criteria for
HCAP was based on a number of considerations, including
the prolonged duration of colonization and possible sub-
sequent infections with resistant bacteria (e.g., S. aureus)
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after hospital discharge [24–26]. The importance of a
prolonged bacterial colonization was also suggested by a
retrospective cohort study involving 639 patients with
culture-positive CAP and HCAP admitted to a single
center, which revealed how patients who were hospitalized
for 2 or more days in the preceding 12 months were also at
risk for MDR pathogens.
In conclusion, our investigation provides important
insights into developing local strategies for treating
patients with HCAP. We found that among patients at high
risk for MDR pathogens, a broad-spectrum empirical
approach may be associated with improved outcome and
reduction in the length of hospitalization. A significant
percentage of patients with HCAP enrolled in a multicenter
national study (about 50 %) had an infection by MDR
pathogens, or an aspiration pneumonia. This epidemio-
logical situation seems to warrant an empirical coverage of
these pathogens until culture results are available. Our
results suggest the importance of recognition of risk factors
for MDR pathogens in patients with HCAP to administer
an appropriate empirical antibiotic treatment.
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